Abstract
The aim of this study was to develop and validate a simple and rapid method for the estimation of the area under the free carboplatin plasma concentration versus time curve (AUC). The relationship between the carboplatin AUC and the total plasma platinum (Pt) concentration 24 h after treatment was studied using data from 49 patients treated with 20–1600 mg/m2 carboplatin as a 60–100 min infusion (median 60 min). The relationship was confirmed by the in vitro incubation of carboplatin in human plasma and prospectively validated in 13 ovarian cancer patients. Free carboplatin was separated by ultrafiltration (MW cut off 30,000), and free and total Pt measured by atomic absorption spectrophotometry. There was a linear relationship in vivo between the 24 h (median 24.4; range 16.3-27.3 h) total plasma Pt concentration (µM) and free carboplatin AUC (mg/ml.min): AUC =(24 h Pt+0.3)/0.82 (r2 =0.93, AUC median 5.8 (0.13-28)mg/ml.min, 24 h Pt median 4.4 (0.1-23) µM). A similar relationship was observed in vitro [AUC =(24 h Pt + 0.1)/0.93 (@#@ r2 =0.98, AUC median 7.9 (2.0-17) mg/ml.min, 24 h Pt median 7.1 (1.8-15) µM)]. The relationship derived from the in vivo data gave an unbiased and reasonably accurate estimate of the measured carboplatin AUC in 13 patients (AUC =5.1-8.7 mg/ml.min, GFR =59-129 ml/min, infusion time 30–45 min, 24 h sampling time 22.9-24.5 h), giving a percentage mean error of -4.2% and root mean squared percentage error of 11.5%. These results show that the analysis of a single blood sample taken 24 h after carboplatin administration can be used to produce an unbiased and reasonably accurate measure of the free carboplatin AUC. Unlike published limited sampling strategies, this method is not complicated by the need to accurately control the duration of the carboplatin infusion or the time at which the sample is taken.
Similar content being viewed by others
References
Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burneil M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748
Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisher J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432
Fournier C, Vennin P, Hecquet B (1988) Correlation between free platinum AUC and total platinum measurement 24hr after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 21:75
Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap K (1984) Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum II in patients with normal and impaired renal function. Cancer Res 44:1693
Harland SJ, Gumbrell LA, Horwich A (1991) Carboplatin dose in combination chemotherapy for testicular cancer. Eur J Cancer 27:691
Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, Peckham MJ, Hendry WF (1991) Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 9:62
Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520
Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH (1987) Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23:1399
Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol 23:367
Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503
Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1991) Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:397
Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324
Vijgh WJF van der (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242
Warmerdam LJC van, Rodenhuis S, Tellingen O van, Maes RAA, Beijnen JH (1994) Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35:179
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ghazal-Aswad, S., Calvert, A.H. & Newell, D.R. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37, 429–434 (1996). https://doi.org/10.1007/s002800050408
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800050408